Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Non Regulatory Announcement

5 Oct 2009 07:00

RNS Number : 1950A
Immunodiagnostic Systems Hldgs PLC
05 October 2009
 



 

Immunodiagnostic Systems Holdings plc

OEM Agreement with Technogenetics of Milan

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that it has signed an OEM manufacturing and supply agreement with Technogenetics s.r.l. of Milan, Italy.

Technogenetics, subsidiary of Bouty S.p.A, is a clinical diagnostics company with particular expertise in diagnostic tests for autoimmune and infectious diseases, as well as being active in endocrinology and molecular biology. 

Under an existing agreement signed in 2007 Technogenetics has been developing automated autoimmune and infectious disease tests for the IDS-iSYS with the intention of selling the IDS instruments and their own test consumables into the Italian market only.

The agreement announced today broadens the scope and nature of this collaboration to permit the sale of Technogenetics products throughout the whole of Europe and the countries of the former Soviet Union. The agreement grants Technogenetics exclusive sales and marketing rights in the fields of autoimmune and infectious disease diagnostics within the specified territories.

The extended area represents approximately 40% of the world wide testing market for autoimmune ($400million) and infectious disease ($500million). Demand for testing continues to grow and the market in these regions is expanding by 5-10% per year. 

IDS will supply IDS-iSYS systems and consumables to Technogenetics on an OEM (Original Equipment Manufacturer) basis in livery appropriate for Technogenetics' sales and marketing operation and these will be sold as badged 'closed system' instruments. 

Technogenetics expects to launch its first range of 20 automated autoimmune IVD products in Q1 2010, with further autoimmune and infectious disease tests to follow later in the year.

Roger Duggan, CEO of IDS, said: "We're very pleased to announce this collaboration which will enhance the sales of IDS-manufactured instruments and ancillary reagents via a non-competing partner. Technogenetics addresses different diagnostic markets to IDS and the automated autoimmune market in particular is poorly-serviced. Both parties are looking forward to buoyant Technogenetics sales in a classical 'Win-Win' situation."

Lorenzo Castellini, chairman of Bouty Group confirms that the extension of the territory provides a significant opportunity to exploit very interesting markets that are core to Technogenetics. Technogenetics is now focusing its efforts in the commercialisation of this opportunity throughout the whole of Europe.

Enquiries:

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

Roger Duggan, CEO

Paul Hailes, Finance Director

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADGMGGGDFGLZM
Date   Source Headline
29th Oct 20077:00 amRNSNotice of Results
5th Oct 200712:11 pmRNSNotifiable Interest
2nd Oct 20077:01 amRNSSenior Management Appointment
17th Sep 20073:33 pmRNSNotifiable Interest
17th Sep 20077:01 amRNSBoard Appointment
10th Sep 20073:48 pmRNSNotifiable Interest
3rd Sep 20077:01 amRNSTotal Voting Rights
3rd Sep 20077:00 amRNSCompletion of Acquisition
31st Aug 20073:16 pmRNSAGM Statement
28th Aug 20071:48 pmRNSResult of EGM
20th Aug 200712:36 pmRNSNotifiable Interest
20th Aug 20079:53 amRNSAIM Rule 26
3rd Aug 20077:00 amRNSProposed Acquisition
31st Jul 200711:03 amRNSTotal Voting Rights
26th Jul 20077:01 amRNSCompletion of acquisition
16th Jul 20075:57 pmRNSCorrection re. dividend dates
16th Jul 20077:01 amRNSFinal Results
29th Jun 20077:01 amRNSNotice of Results
18th Jun 20077:02 amRNSImmunoassay kits agreement
8th May 20077:01 amRNSNotifiable Interest
3rd May 20073:39 pmRNSDirectors Dealing
21st Mar 20077:00 amRNSTrading Statement
20th Mar 20075:33 pmRNSNotifiable Interest
13th Mar 20077:00 amRNSBoard Appointment
12th Feb 20077:02 amRNSBoard Appointment
31st Jan 20077:02 amRNSProduct launch
4th Jan 20077:00 amRNSProduct Launch
21st Dec 200612:48 pmRNSTotal Voting Rights
5th Dec 20069:44 amRNSDirector/PDMR Shareholding
4th Dec 20067:02 amRNSAutomation agreement
15th Nov 20068:54 amRNSHolding(s) in Company
6th Nov 20067:01 amRNSInterim Results
19th Oct 200611:34 amRNSNotice of Results
10th Oct 20067:02 amRNSIDS launches into Austria
13th Sep 20067:00 amRNSLaunch of new assay kit
22nd Aug 200611:04 amRNSAGM Statement
17th Jul 20064:35 pmRNSHolding(s) in Company
5th Jul 20067:00 amRNSFinal Results
30th May 20067:03 amRNSMarketing & sales agreement
15th May 20067:01 amRNSDirectorate Change
12th Apr 20067:01 amRNSDirector/PDMR Shareholding
30th Mar 20067:01 amRNSPre-close Trading update
21st Feb 20062:38 pmRNSDirectors Dealing
7th Nov 20057:00 amRNSInterim Results
26th Oct 20059:52 amRNSNotice of Results
26th Sep 20057:01 amRNSBoard Appointment
6th Sep 200511:18 amRNSAGM Statement
12th Aug 200510:42 amRNSFDA Approval
12th Jul 20057:01 amRNSFinal Results
6th Jul 20053:19 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.